Hypoprothrombinemia and severe perioperative haemorrhagic complications in cardiac surgery patients treated with high-dose cefazolin for infective endocarditis

Anaesth Crit Care Pain Med. 2018 Apr;37(2):167-170. doi: 10.1016/j.accpm.2017.07.006. Epub 2017 Sep 1.

Abstract

Endocarditis is a serious and common disease that requires prolonged antimicrobial therapy. The recent shortage of oxacillin has led to the use of other antimicrobial agents such as cefazolin to treat endocarditis due to methicillin-sensitive Staphylococcus aureus. We describe four cases of life-threatening haemorrhagic complications (fatal in two cases) in patients treated with high-dose cefazolin. All of these patients with major bleeding presented with hypoprothrombinemia secondary to hypovitaminosis K. This adverse event may be due to inhibition of vitamin K epoxide reductase and/or gamma-glutamyl-carboxylase by the 2-methyl-1,2,3-thiadiazol-5-thiol group of cefazolin. This inhibition may result in hypoprothrombinemia by altering the synthesis of vitamin K-dependent coagulation factors. The increasing use of cefazolin, especially at a high dose and for a prolonged period of time, should be accompanied by regular monitoring of coagulation, including prothrombin index, and vitamin K supplementation.

Keywords: Adverse events; Cefazolin; Endocarditis; Haemorrhage; Hypoprothrombinemia; Vitamin K deficiency.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Bacterial Agents
  • Blood Loss, Surgical*
  • Cardiac Surgical Procedures*
  • Cardiac Tamponade / etiology
  • Cefazolin / adverse effects*
  • Cefazolin / therapeutic use*
  • Endocarditis / complications*
  • Endocarditis / drug therapy*
  • Endocarditis / microbiology
  • Fatal Outcome
  • Gastrointestinal Hemorrhage / etiology
  • Heart Valve Prosthesis Implantation
  • Hemorrhage / chemically induced*
  • Hemorrhage / mortality
  • Hemorrhage / therapy*
  • Humans
  • Hypoprothrombinemias / chemically induced*
  • Hypoprothrombinemias / mortality
  • Hypoprothrombinemias / therapy*
  • Male
  • Methicillin-Resistant Staphylococcus aureus
  • Prothrombin Time
  • Vitamin K Deficiency / chemically induced

Substances

  • Anti-Bacterial Agents
  • Cefazolin